NantKwest to Host Investor Day on January 14, 2016

CULVER CITY, Calif.--(BUSINESS WIRE)-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using natural killer cells to treat cancer, infectious diseases and inflammatory diseases, announced today that it will hold an R&D day on Thursday, January 14, 2016 at 12 p.m. PT in San Francisco, CA.

The R&D Day will be hosted by key members of the NantKwest’s executive leadership team. The team will provide an overview of the Company's pipeline, followed by a question-and-answer session after the formal presentations.

In-person attendance at the R&D Day is by invitation only. A slide presentation and a live audio webcast will be available on the Company's website at www.nantkwest.com and a replay of the webcast will be made available approximately two hours following the completion of the events.

About NantKwest Inc.

NantKwest (Nasdaq: NK) is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells are the body’s first line of defense due to the innate ability of NK cells to rapidly identify and destroy cells under stress, such as cancer or virally-infected cells.

NantKwest’s unique NK cell-based platform, with the capacity to grow active killer cells as a biological cancer therapy, has been designed to induce cell death against cancer or infected cells by three different modes of action: (1) Direct killing using activated NK cells (aNK) that release toxic granules directly into the cell through cell to cell contact, (2) Antibody-mediated killing using haNKs, which are NK cells engineered to incorporate a high affinity receptor that binds to an administered antibody, enhancing the cancer cell killing effect of that antibody, and (3) Targeted activated killing using taNKs, which are NK cells engineered to incorporate chimeric antigen receptors (CARs) to target tumor-specific antigens found on the surface of cancer cells.

Our aNK, haNK and taNK platform addresses certain limitations of T cell therapies including the reduction of risk of serious "cytokine storms" reported after T cell therapy. As an “off-the-shelf” therapy, NantKwest's NK cells do not rely on a patient’s own often compromised immune system. In Phase 1 clinical trials in patients with late stage cancer, NantKwest's NK cells have been successfully administered as an outpatient infusion therapy without any reported severe side effects, even at doses of 10 billion cells.

By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs that include a Phase 2 trial for a rare form of melanoma and the planned initiation of a clinical trial of NK cells targeted to breast cancer, we believe NantKwest is uniquely positioned to be the premier immunotherapy company and transform medicine by delivering living drugs in a bag and bringing novel NK cell-based therapies to routine clinical care. For more information please visit http://www.nantkwest.com and follow Dr. Soon-Shiong on Twitter@solvehealthcare.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151222005212/en/

Media
NantKwest
Jen Hodson, 562-397-3639
[email protected]
or
Investors
[email protected]

Source: NantKwest, Inc.

You May Also Be Interested In

• The Apex Institute Reveals What Hiring Managers Actually Want in Cloud and AI Infrastructure Roles
• NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.
• Bitcoin News Goes Wild at $77K While Smart Money Quietly Loads Pepeto